

Table S2. Clinical evaluation of aspirin resistance

Authors	Speciality	Study Design	Assay	No. Participants	Clinical outcomes reported
Chu J et al 2010 ¹	Cardiology	Prospective dose escalation study	VerifyNow Aspirin Test	314	Acute MI (index admission), major adverse cardiac events including cardiovascular death or recurrent ACS requiring hospitalization within 6 months.
Poulsen T et al 2007 ²	Cardiology	Prospective cohort study	PFA-100 Collagen/Epinephrine cartridges	277	Acute MI at index admission.
Cotter G et al 2004 ³	Cardiology	Prospective cohort Study	Plasma Thromboxane B2	73	Cardiovascular events, including death, reinfarction, and readmission for unstable angina, and cardiovascular readmission.
Glauser J et al 2010 ⁴	Cardiology	Prospective cohort study	VerifyNow Aspirin Test	200	Composite end point; 30-day revisit, positive cardiac catheterization, or hospital length of stay longer than 3 days
Chen W et al 2007 ⁵	Cardiology	Prospective cohort study	VerifyNow Aspirin Test	468	Composite of cardiovascular death, myocardial infarction (MI), unstable angina requiring hospitalization, stroke, and transient ischemic attack.
Hobikoglu G et al 2007 ⁶	Cardiology	Prospective cohort Study	PFA-100 Collagen/Epinephrine Cartridges	140	Composite of death, myocardial infarction, cerebrovascular accident and revascularization.
Cao J et al 2012 ⁷	Cardiology	Prospective cohort study	LTA, TEG	269	Composite of death, myocardial infarction, unstable angina, stroke and transient ischemic attack.
Christiaens L et al 2008 ⁸	Cardiology	Prospective cohort study	PFA-100 Collagen/Epinephrine cartridges	97	Composite of death, myocardial infarction, and ischemic cerebral infarction or acute limb ischemia.
Poulsen T et al 2007 ⁹	Cardiology	Prospective cohort study	PFA-100 Collagen/Epinephrine cartridges	187	Death, admission with recurrent MI, stroke or mechanical revascularization of atherothrombotic disease.
Eikelboom J et al 2002 ¹⁰	Cardiology	Nested case-control study	Urinary 11-Dehydrothromboxane B2	976 total (including 488 controls)	Composite outcome of MI, stroke, or cardiovascular death.
Addad F et al 2010 ¹¹	Cardiology	Prospective cohort study	PFA-100 Collagen/Epinephrine cartridges	204	Major Cardiac Adverse Events: cardiovascular death, MI, stroke or TIA. The secondary endpoint was the occurrence of Recurrent Acute Vascular Event; MI, stroke or TIA).
Pamukcu B et al 2006 ¹²	Cardiology	Prospective cohort study	PFA-100 Collagen/Epinephrine cartridges	105	MI, unstable Angina, Cardiac Death

Andersen K et al 2002 ¹³	Cardiology	Randomised comparative study	PFA-100 Collagen/Epinephrine cartridges	71 (taking aspirin alone)	Non-fatal reinfarction/MI and stroke, secondary endpoint of need for revascularizations (CABG or percutaneous coronary intervention (PCI)).
Gum P et al 2003 ¹⁴	Cardiology	Prospective cohort study	LTA	326	Composite of death, MI, or cerebrovascular accident.
Sullivan M et al 1993 ¹⁵	High-risk obstetrics	Prospective cohort study	LTA	6	Pre-eclampsia
Rey et al 2011 ¹⁶	High-risk obstetrics	Retrospective cohort study	PFA-100 Collagen/Epinephrine cartridges	270	Pre-eclampsia, early-onset pre-eclampsia, severe pre-eclampsia
Wojtowicz A et al 2011 ¹⁷	High-risk obstetrics	Prospective cohort study	Urinary 11-dehydrothromboxane B2	43 (taking aspirin)	Preterm birth, pre-eclampsia, SGA infants.
Kilickesmez K et al 2013 ¹⁸	Nephrology	Prospective Cohort Study	Multiplate ASPI Test	78	Composite of death, MI, unstable angina, or CVA. Secondary end points were the individual events of death, MI, unstable angina, and CVA.
Zheng A et al 2013 ¹⁹	Stroke Medicine	Prospective cohort Study	VerifyNow Aspirin Test	90	Clinical stroke severity and infarct size.
Boncoraglio G et al 2009 ²⁰	Stroke Medicine	Prospective cohort study	PFA-100 Collagen/Epinephrine cartridges	129	Composite of stroke, TIA, myocardial infarction, and cardiovascular death.
Helgason C et al 1994 ²¹	Stroke Medicine	Prospective dose escalation study	LTA	146	Cerebral ischaemic events.
McCabe D et al 2005 ²²	Stroke Medicine	Prospective cohort study	PFA-100 Collagen/Epinephrine cartridges	103	Further stroke or TIA.
Lai P et al 2012 ²³	Stroke Medicine	Prospective cohort study	PFA-100 Collagen/Epinephrine cartridges	224	National Institutes of Health Stroke Scale and modified Rankin Scale scores
Berrouschott J et al 2006 ²⁴	Stroke Medicine	Prospective dose escalation study	LTA	291	Recurrent stroke.

References for Table S2

1. Chu JW, Wong CK, Chambers J, Wout JV, Herbison P, Tang EW, et al. Aspirin resistance determined from a bed-side test in patients suspected to have acute coronary syndrome portends a worse 6 months outcome. *QJM: An International Journal of Medicine*. 2010;103(6):405.
2. Poulsen TS, Oslash, Rgensen B, Korsholm L, Bj, Oslash, et al. Prevalence of aspirin resistance in patients with an evolving acute myocardial infarction. *Thrombosis Research*. 2007;119(5):555.

3. Cotter G, Shemesh E, Zehavi M, Dinur I, Rudnick A, Milo O, et al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin? *American Heart Journal*. 2004;147(2):293.
4. Glauser J, Emerman CL, Bhatt DL, Peacock WF, Glauser J, Emerman CL, et al. Platelet aspirin resistance in ED patients with suspected acute coronary syndrome. *The American Journal of Emergency Medicine*. 2010;28(4):440.
5. Chen W-H, Cheng X, Lee P-Y, Ng W, Kwok JY-Y, Tse H-F, et al. Aspirin Resistance and Adverse Clinical Events in Patients with Coronary Artery Disease. *American Journal of Medicine*. 2007;120(7):631.
6. Hobikoglu GF, Norgaz T, Aksu H, Ozer O, Erturk M, Destegul E, et al. The effect of acetylsalicylic acid resistance on prognosis of patients who have developed acute coronary syndrome during acetylsalicylic acid therapy. *Canadian Journal of Cardiology*. 2007;23(3):201.
7. Cao J, Liu L, Fan L, Chen T, Hu G, Hu Y, et al. The prevalence, risk factors and prognosis of aspirin resistance in elderly male patients with cardiovascular disease. *The Aging Male*. 2012;15(3):140.
8. Christiaens L, Ragot S, Mergy J, Allal J, Macchi L. Major clinical vascular events and aspirin-resistance status as determined by the PFA-100 method among patients with stable coronary artery disease: a prospective study. *Blood Coagulation & Fibrinolysis : An International Journal in Haemostasis and Thrombosis*. 2008;19(3):235.
9. Poulsen TS, Kristensen S, Oslash, Ren R, Korsholm L, Haghfelt T, et al. Variation and importance of aspirin resistance in patients with known cardiovascular disease. *Thrombosis Research*. 2007;120(4):477.
10. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. *Circulation*. 2002;105(14):1650-5.
11. Addad F, Chakroun T, Abderazek F, Ben-Farhat M, Hamdi S, Dridi Z, et al. Response variability to aspirin and one-year prediction of vascular events in patients with stable coronary artery disease. *Journal of Thrombosis and Thrombolysis*. 2010;29(1):108.
12. Pamukcu B, Oflaz H, Oncul A, Umman B, Mercanoglu F, Ozcan M, et al. The role of aspirin resistance on outcome in patients with acute coronary syndrome and the effect of clopidogrel therapy in the prevention of major cardiovascular events. *Journal of Thrombosis and Thrombolysis*. 2006;22(2):103.
13. Andersen K, Hurlen M, Arnesen H, Seljeflot I, Oslash, Rg, et al. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. *Thrombosis Research*. 2002;108(1):37.

14. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. Clinical study: antiplatelet therapy: A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. *Journal of the American College of Cardiology*. 2003;41:961-5.
15. Sullivan MHF, Elder MG. Changes in platelet reactivity following aspirin treatment for pre-eclampsia. *BJOG: An International Journal of Obstetrics & Gynaecology*. 1993;100(6):542.
16. Rey E, Rivard G-E. Is testing for aspirin response worthwhile in high-risk pregnancy? *European Journal of Obstetrics and Gynecology*. 2011;157:38-42.
17. Wojtowicz A, Undas A, Huras H, Musial J, Rytlewski K, Reron A, et al. Aspirin resistance may be associated with adverse pregnancy outcomes. *Neuroendocrinology Letters*. 2011;32(3):334-9.
18. Kilickesmez KO, Kocas C, Abaci O, Okcun B, Gurmen T, Gorcin B. Follow-up of aspirin-resistant patients with end-stage kidney disease. *International Urology and Nephrology*. 2012:1-6.
19. Zheng AS, Churilov L, Colley RE, Goh C, Davis SM, Yan B, et al. Association of Aspirin Resistance With Increased Stroke Severity and Infarct Size. *JAMA Neurology*. 2013;70(2):208.
20. Boncoraglio GB, Bodini A, Brambilla C, Corsini E, Carriero MR, Parati EA. Aspirin resistance determined with PFA-100 does not predict new thrombotic events in patients with stable ischemic cerebrovascular disease. *Clinical Neurology and Neurosurgery*. 2009;111(3):270-3.
21. Helgason CM, Bolin KM, Hoff JA, Winkler SR, Mangat A, Tortorice KL, et al. Development of aspirin resistance in persons with previous ischemic stroke. *Stroke*. 1994;25(12):2331.
22. McCabe DJ, Harrison P, Mackie IJ, Sidhu PS, Lawrie AS, Purdy G, et al. Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA. *Platelets*. 2005;16(5):269.
23. Lai P-T, Chen S-Y, Lee Y-S, Ho Y-P, Chiang Y-Y, Hsu H-Y, et al. Relationship between acute stroke outcome, aspirin resistance, and humoral factors. *Journal of the Chinese Medical Association*. 2012;75(10):513.
24. Berrouschot J, Schwetlick B, von Twickel G, Fischer C, Uhlemann H, Siegemund T, et al. Aspirin resistance in secondary stroke prevention. *Acta Neurologica Scandinavica*. 2006;113(1):31-5.